We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
Melanotan-1 is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Melanotan-1 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1988–2015 with a typical study size of 77 participants.
Based on 5 studies · 1 RCT · 77 total participants
Confidence
LowBy outcome
The current evidence for Melanotan-1 is insufficient to assign an evidence score, based on 5 indexed studies. A grey-market injectable α-MSH analog sold for tanning ('the Barbie drug'). Chemically it is the SAME peptide as the approved drug afamelanotide (Scenesse). Honest appraisal: as an unregulated tanning injectable it has no efficacy/safety validation; its evidence base belongs to the regulated form for a rare blood disorder. Research-use-only. Representative study: PMID 16293341.
The commonly studied dose of Melanotan-1 is No validated dose for cosmetic tanning. Grey-market injectable use is unapproved; the legitimate, evidence-based form of this peptide is the prescription afamelanotide (Scenesse) implant for erythropoietic protoporphyria — see that entry.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Melanotan I ([Nle4, D-Phe7]-α-MSH; same peptide as afamelanotide)
A grey-market injectable α-MSH analog sold for tanning ('the Barbie drug'). Chemically it is the SAME peptide as the approved drug afamelanotide (Scenesse). Honest appraisal: as an unregulated tanning injectable it has no efficacy/safety validation; its evidence base belongs to the regulated form for a rare blood disorder. Research-use-only.
As a grey-market self-injected tanning peptide, Melanotan-1 has no controlled efficacy or safety evidence; the real trial evidence for this molecule belongs to its regulated form, afamelanotide (Scenesse), for erythropoietic protoporphyria — not for cosmetic tanning.
Melanotan I ([Nle4, D-Phe7]-α-MSH, also called NDP-MSH) is a potent synthetic analog of α-melanocyte-stimulating hormone that activates the MC1 receptor to increase eumelanin (skin pigmentation).
It is important to be clear that Melanotan-1 is chemically the same peptide as afamelanotide, the regulated implant marketed as Scenesse and approved to reduce phototoxicity in erythropoietic protoporphyria (a rare, painful light-sensitivity disorder) — see the separate afamelanotide entry for that medical use and its trial evidence.
This entry covers the grey-market reality: 'Melanotan I' sold online as a self-injected 'tanning jab' for cosmetic skin darkening, an unapproved use.
There are no controlled trials supporting cosmetic tanning efficacy or safety for the injectable grey-market product, and self-injection carries the usual purity/sterility risks plus melanocortin side effects (nausea, facial flushing, appetite changes) and dermatologic concerns — darkening and change of moles and new nevi, which complicates melanoma surveillance.
Because it stimulates melanocytes, dermatologists have raised concern about its use in people with many naevi or melanoma risk. Used medically as afamelanotide it is a legitimate, evidence-backed drug; sold as a grey-market tanning peptide it is unregulated and not recommended.
The score reflects the absence of validated evidence for the grey-market tanning use.
Melanotan-1 is a potent, slowly-degraded agonist at the melanocortin-1 receptor on melanocytes, driving eumelanin synthesis and skin darkening.
Increased eumelanin provides some photoprotection (the basis of the afamelanotide indication) but also darkens existing pigmented lesions.
How Melanotan-1 works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated dose for cosmetic tanning. Grey-market injectable use is unapproved; the legitimate, evidence-based form of this peptide is the prescription afamelanotide (Scenesse) implant for erythropoietic protoporphyria — see that entry.
Can be taken without food
| Form | Type |
|---|---|
| 💊None established for grey-market use (research peptide) | Recommended |
| 💊Regulated form: afamelanotide 16 mg subcutaneous implant (Scenesse) — prescription only | Alternative |
Grey-market 'Melanotan I' is a self-injected lyophilized peptide for tanning; the same molecule as the approved implant afamelanotide, but unregulated and unvalidated for cosmetic use.
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: No validated cosmetic dosing. The regulated form (afamelanotide/Scenesse) is a clinician-placed implant on a defined schedule — see that entry.
Dose-response data unavailable. The current published research for Melanotan-1 does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Increases eumelanin and tans the skin via MC1R activation — the marketed grey-market effect.
Nausea, facial flushing, and appetite changes are common with melanocortin agonists.
Darkening and change of existing moles and appearance of new nevi can complicate melanoma surveillance; concerning in those with many naevi or melanoma risk.
Avoid — melanocyte stimulation darkens/changes nevi and complicates melanoma surveillance.
Avoid — no safety data for cosmetic melanocortin use.
Does not replace sunscreen/UV avoidance; increased pigment is only partial photoprotection.
Tip: Common melanocortin effect after dosing; transient.
Tip: Have a dermatologist monitor pigmented lesions; avoid with many naevi or melanoma risk.
Tip: Inherent to grey-market self-injection; sterility unverified.
Timing is flexible for Melanotan-1 — consistent daily use matters more than the time of day. No validated cosmetic dosing; grey-market 'tanning jab' regimens are anecdotal.
Melanotan-1 should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea / facial flushing, darkening / change of moles, new nevi, injection-site reaction / infection. Use caution if any of these apply to you: Pregnancy / breastfeeding; Melanoma or many atypical moles (melanocyte stimulation / surveillance concern); Cosmetic tanning use (unapproved, no safety validation).
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.